Unpleasant symptoms of immunotherapy for people with lung cancer: A mixed-method study

作者全名："Zhang, Jingyu; Wang, Sichao; Zhou, Zihao; Lei, Cheng; Yu, Hongfan; Zeng, Cheng; Xia, Xin; Qiao, Guibing; Shi, Qiuling"

作者地址："[Zhang, Jingyu; Yu, Hongfan; Shi, Qiuling] Chongqing Med Univ, Coll Biomed Engn, State Key Lab Ultrasound Med & Engn, Chongqing, Peoples R China; [Wang, Sichao; Zhou, Zihao; Zeng, Cheng; Xia, Xin; Qiao, Guibing] Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Thorac Surg, Guangzhou, Peoples R China; [Lei, Cheng; Shi, Qiuling] Chongqing Med Univ, Sch Publ Hlth, Chongqing, Peoples R China; [Wang, Sichao] Univ Hong Kong, LKS Fac Med, Dept Clin Oncol, Hong Kong, Peoples R China; [Zeng, Cheng; Qiao, Guibing] Southern Med Univ, Sch Clin Med 2, Guangzhou, Peoples R China; [Qiao, Guibing] Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Thorac Surg, 106,Zhongshan 2nd Rd, Guangzhou 510080, Peoples R China; [Shi, Qiuling] Chongqing Med Univ, Coll Biomed Engn, State Key Lab Ultrasound Med & Engn, 1,Med Coll Rd, Chongqing 400016, Peoples R China"

通信作者："Qiao, GB (通讯作者)，Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Thorac Surg, 106,Zhongshan 2nd Rd, Guangzhou 510080, Peoples R China.; Shi, QL (通讯作者)，Chongqing Med Univ, Coll Biomed Engn, State Key Lab Ultrasound Med & Engn, 1,Med Coll Rd, Chongqing 400016, Peoples R China."

来源：INTERNATIONAL JOURNAL OF NURSING STUDIES

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000991781100001

JCR分区：Q1

影响因子：7.5

年份：2023

卷号：139

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：Immunotherapy; Lung cancer; Patient -reported outcome; Unpleasant symptom

摘要："Background: Immunotherapy has changed the outlook for lung cancer treatment. A closer look at the accompanying symptoms from the patient's perspective is necessary to improve their tolerance to the treatment, which is also the basis for standardized symptom management. Objective: To describe the symptomatic experiences of patients receiving immunotherapy for lung cancer and explore whether symptoms reported during immunotherapy were associated with survival outcomes. Design: Exploratory sequential mixed-method study. Settings: Patients were continuously recruited from the oncology day ward of Guangdong Provincial People's Hospital between October 2019 and January 2020. Participants: 59 patients with advanced lung cancer and receiving immunotherapy (median [IQR] age was 64 [58-69]; 72.9 % pathological stage was IV) were included in the study. Methods: A sequential qualitative interview on symptom experiences was conducted from the perspective of lung cancer patients in immunotherapy. Summative content analysis was used to develop a standardized symptom reporting checklist. Survival outcome follow-ups of each patient were conducted 2 years after the interview. Results: 47 symptoms were extracted from the 124 interviews of 59 patients, the common symptoms including musculoskeletal pain (52.5 %), itchy skin (45.8 %), fatigue (45.8 %), cough (44.1 %), shortness of breath (32.2 %), lack of appetite (32.2 %), and rashes (32.2 %). The timing, severity, and interference of symptoms were different among patients. The symptoms of shortness of breath, fatigue and chest pain were more common in chemoimmunotherapy, while dry mouth and blurred vision were more frequent with immunotherapy. The symptoms of musculoskeletal pain, shortness of breath, lack of appetite, drowsiness and taste change were more common for those who died two years after the interviews; for those who survived, the symptoms of rash and chill were more common. Conclusions: We generated a symptom list related to lung cancer immunotherapy from the patients, provided a closer look at symptoms from the patient's perspective, and suggested differences in the presence of symptoms between the group of treatment and survival outcome. This enables clinicians and nurses to better understand and empathize with the patient's experience, so as to truly practice the essence of patient-centered care, and provide a basis for the development of standardized symptom measurement tools in the future. Tweetable abstract: At least 47 unpleasant symptoms were present in immunotherapy from the perspective of lung cancer patients."

基金机构："Medical Scientific Research Founda-tion of Guangdong Province, China [A2029043]; Graduate Student Research Innovation Project of Chongqing, China [CYB21193]"

基金资助正文："Funding This research was supported by Medical Scientific Research Founda-tion of Guangdong Province, China (A2029043) and Graduate Student Research Innovation Project of Chongqing, China (CYB21193) ."